Kezar Life Sciences IncNASDAQ:KZRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6942
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.6942/ 3
- Ask / Lots0.7099/ 80
- Open / Previous Close0.0000 / 0.6942
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 1167 | 0.7133 |
| 09:34 ET | 100 | 0.71 |
| 09:38 ET | 450 | 0.7 |
| 09:45 ET | 180 | 0.7092 |
| 09:48 ET | 300 | 0.7 |
| 09:52 ET | 100 | 0.7 |
| 09:56 ET | 100 | 0.7 |
| 09:59 ET | 300 | 0.7 |
| 10:03 ET | 1100 | 0.7003 |
| 10:06 ET | 1400 | 0.7092 |
| 10:08 ET | 777 | 0.7003 |
| 10:10 ET | 890 | 0.7097 |
| 10:12 ET | 200 | 0.7003 |
| 10:14 ET | 100 | 0.7003 |
| 10:15 ET | 4650 | 0.708 |
| 10:26 ET | 2300 | 0.70285 |
| 10:28 ET | 100 | 0.7003 |
| 10:30 ET | 400 | 0.7024 |
| 10:32 ET | 4030 | 0.7049 |
| 10:33 ET | 3354 | 0.704 |
| 10:35 ET | 6855 | 0.7047 |
| 10:37 ET | 3745 | 0.7047 |
| 10:39 ET | 1400 | 0.7053 |
| 10:42 ET | 300 | 0.7094 |
| 10:44 ET | 365 | 0.708599 |
| 10:48 ET | 250 | 0.7087 |
| 10:50 ET | 100 | 0.7007 |
| 10:51 ET | 100 | 0.7087 |
| 10:53 ET | 900 | 0.700801 |
| 10:55 ET | 500 | 0.7047 |
| 10:57 ET | 900 | 0.7048 |
| 11:02 ET | 200 | 0.7086 |
| 11:04 ET | 100 | 0.7009 |
| 11:06 ET | 500 | 0.7086 |
| 11:08 ET | 100 | 0.7009 |
| 11:09 ET | 200 | 0.7009 |
| 11:11 ET | 100 | 0.7011 |
| 11:13 ET | 200 | 0.7049 |
| 11:15 ET | 100 | 0.7011 |
| 11:18 ET | 200 | 0.7011 |
| 11:20 ET | 200 | 0.7011 |
| 11:22 ET | 200 | 0.7011 |
| 11:24 ET | 324 | 0.7086 |
| 11:26 ET | 100 | 0.7011 |
| 11:27 ET | 293 | 0.7011 |
| 11:31 ET | 1337 | 0.7031 |
| 11:36 ET | 300 | 0.705 |
| 11:38 ET | 954 | 0.703 |
| 11:40 ET | 100 | 0.703 |
| 11:42 ET | 100 | 0.70345 |
| 11:47 ET | 1232 | 0.7045 |
| 11:51 ET | 4958 | 0.6939 |
| 11:54 ET | 100 | 0.6927 |
| 11:56 ET | 200 | 0.6874 |
| 11:58 ET | 6627 | 0.6937 |
| 12:00 ET | 200 | 0.69 |
| 12:02 ET | 1000 | 0.6936 |
| 12:03 ET | 629 | 0.69165 |
| 12:05 ET | 400 | 0.6933 |
| 12:07 ET | 100 | 0.6848 |
| 12:12 ET | 1100 | 0.6933 |
| 12:14 ET | 700 | 0.6848 |
| 12:18 ET | 1000 | 0.69 |
| 12:20 ET | 300 | 0.6869 |
| 12:23 ET | 5280 | 0.687 |
| 12:25 ET | 567 | 0.6883 |
| 12:27 ET | 200 | 0.6883 |
| 12:30 ET | 300 | 0.6869 |
| 12:32 ET | 200 | 0.6869 |
| 12:34 ET | 200 | 0.6869 |
| 12:36 ET | 1200 | 0.6844 |
| 12:38 ET | 100 | 0.6844 |
| 12:39 ET | 400 | 0.6844 |
| 12:41 ET | 8300 | 0.689 |
| 12:43 ET | 300 | 0.6848 |
| 12:45 ET | 200 | 0.6832 |
| 12:50 ET | 3694 | 0.69 |
| 12:52 ET | 200 | 0.69 |
| 12:54 ET | 200 | 0.6916 |
| 01:01 ET | 400 | 0.6916 |
| 01:06 ET | 1847 | 0.6902 |
| 01:08 ET | 325 | 0.6901 |
| 01:10 ET | 1227 | 0.6835 |
| 01:17 ET | 432 | 0.6888 |
| 01:21 ET | 1200 | 0.6887 |
| 01:24 ET | 100 | 0.6836 |
| 01:28 ET | 100 | 0.6836 |
| 01:30 ET | 300 | 0.6836 |
| 01:33 ET | 1100 | 0.6863 |
| 01:35 ET | 100 | 0.6863 |
| 01:37 ET | 600 | 0.6863 |
| 01:39 ET | 200 | 0.6887 |
| 01:42 ET | 1825 | 0.6839 |
| 01:46 ET | 100 | 0.6839 |
| 01:48 ET | 500 | 0.6842 |
| 01:50 ET | 660 | 0.6858 |
| 01:51 ET | 100 | 0.6849 |
| 01:53 ET | 784 | 0.685 |
| 01:57 ET | 400 | 0.684 |
| 02:00 ET | 200 | 0.6839 |
| 02:02 ET | 100 | 0.6849 |
| 02:06 ET | 1600 | 0.6849 |
| 02:13 ET | 100 | 0.6845 |
| 02:15 ET | 200 | 0.6845 |
| 02:18 ET | 2200 | 0.6845 |
| 02:20 ET | 100 | 0.6833 |
| 02:22 ET | 100 | 0.6833 |
| 02:24 ET | 5490 | 0.6834 |
| 02:26 ET | 900 | 0.68445 |
| 02:27 ET | 702 | 0.68445 |
| 02:29 ET | 600 | 0.685 |
| 02:31 ET | 1695 | 0.6898 |
| 02:38 ET | 100 | 0.6901 |
| 02:40 ET | 100 | 0.6917 |
| 02:44 ET | 17480 | 0.6926 |
| 02:45 ET | 400 | 0.6988 |
| 02:49 ET | 100 | 0.699 |
| 02:51 ET | 880 | 0.699 |
| 02:54 ET | 11156 | 0.6989 |
| 02:56 ET | 200 | 0.6981 |
| 02:58 ET | 1100 | 0.6955 |
| 03:00 ET | 300 | 0.6949 |
| 03:03 ET | 100 | 0.6962 |
| 03:05 ET | 100 | 0.6949 |
| 03:09 ET | 100 | 0.6949 |
| 03:12 ET | 100 | 0.6949 |
| 03:14 ET | 300 | 0.6954 |
| 03:16 ET | 500 | 0.6934 |
| 03:18 ET | 150 | 0.6973 |
| 03:20 ET | 400 | 0.6903 |
| 03:21 ET | 1608 | 0.69395 |
| 03:23 ET | 1226 | 0.6939 |
| 03:25 ET | 300 | 0.6972 |
| 03:27 ET | 200 | 0.695 |
| 03:30 ET | 400 | 0.69495 |
| 03:32 ET | 200 | 0.6948 |
| 03:36 ET | 260 | 0.697 |
| 03:38 ET | 100 | 0.6969 |
| 03:39 ET | 200 | 0.6906 |
| 03:41 ET | 900 | 0.6906 |
| 03:43 ET | 100 | 0.6906 |
| 03:45 ET | 1263 | 0.6906 |
| 03:48 ET | 400 | 0.6908 |
| 03:50 ET | 936 | 0.6939 |
| 03:52 ET | 517 | 0.6909 |
| 03:54 ET | 1600 | 0.6964 |
| 03:56 ET | 600 | 0.6935 |
| 03:57 ET | 1200 | 0.6927 |
| 03:59 ET | 3130 | 0.6942 |
Jun 7, 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), from 5:59PM ET on Friday Jun 07, 2024 by Dow Jones
5:59PM ET on Friday Jun 07, 2024 by Dow Jones
May 29, 2024
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference, from 4:01PM ET on Wednesday May 29, 2024 by Dow Jones
4:01PM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 51.7M | -0.5x | --- |
LAVA Therapeutics NV | 60.5M | -2.2x | --- |
DURECT Corp | 48.4M | -2.0x | --- |
BioLine RX Ltd | 54.9M | -0.9x | --- |
Curis Inc | 51.9M | -1.0x | --- |
Atara Biotherapeutics Inc | 65.6M | -0.2x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Director
- Christopher Kirk
- Chief Financial Officer
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $51.7M |
|---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 72.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.29 |
EPS | $-1.40 |
Book Value | $2.58 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,591.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
